Applications for the 6th edition of the Multiple Myeloma Research Grant are open. This is an initiative of the Portuguese Association Against Leukemia (APCL) and the Portuguese Society of Hematology (SPH), with the support of Amgen Biofarmacêutica.
The Research Grant, worth 15 thousand euros, aims to promote and reward national research projects that contribute to the progress of scientific knowledge and the state of the art in a rare hemato-oncological disease, with no cure to date – Multiple Myeloma . Applications are open from May 6th to September 15th of this year.
The research projects presented can be carried out by national or foreign researchers working in Portuguese institutions, with collaboration and partnership between various institutions being encouraged, as well as interdisciplinarity. All applications must be sent to the following email: bolsas@apcl.pt, by midnight on September 15, 2024.
According to Manuel Abecasis, president of APCL, «It is with great enthusiasm that we launch this 6th edition of the Multiple Myeloma Research Grant. The research teams have shown a lot of interest, which is why we are looking forward to the number of applications we will receive, but also in relation to the projects. Previous editions have raised the bar, with innovative projects in terms of research and treatment, with an impact on patients’ unmet needs».
According to Maria Gomes da Silva, president of SPH, “It is essential to continue investing in national research and the contribution of this scholarship to the development of the distinguished projects has been visible and very important. Multiple myeloma is a rare and until now incurable hemato-oncological pathology, which is why all research that can contribute to timely detection, more effective treatment, progress in the characterization of the disease and an improvement in the quality of life of patients is very relevant. sick. We believe in the true impact of these projects.”
«The Multiple Myeloma Research Grant is in its 6th edition, a longevity that reflects the quality of the projects that have been presented and the impact they have had on research. We want to continue contributing so that new solutions can improve the care provided to patients with multiple myeloma, with an impact on the management of their disease and quality of life», says Tiago Amieiro, general director of Amgen Biofarmacêutica.
All submitted projects will be evaluated by a suitable jury, composed of experts of recognized merit in scientific research and professional and/or academic experience in hemato-oncology in Portugal and/or internationally, appointed by APCL and SPH. The regulations for the Multiple Myeloma research grant can be consulted on the partners’ websites.
Multiple Myeloma is the second most common haematological neoplasm in Portugal with around 544[1] new cases per year. This pathology has a high incidence after the age of 50 and presents non-specific, sometimes undervalued symptoms, with timely diagnosis being essential to maximize health outcomes in these patients.
[1] National Oncological Registry 2018, available at this link.
Follow us on Facebook, Twitter, Instagram, Youtube, and TikTok and see the exclusive content for social networks.
